 |
Brennen Medical, LLC announces the sale of its XenMatrix device to Davol Inc., a subsidiary of C.R. Bard, Inc. The agreement provides Davol with the worldwide rights and related assets of the hernia products business of Brennen Medical, LLC. This acquisition includes technology for a non-crosslinked xenograft device for use in soft tissue repair including hernia and abdominal wall reconstruction. Features include:
- A proprietary technology that maintains an acellular structurally intact, non crosslinked porcine dermal matrix for enhanced biocompatibility in host tissue.
- A dermal matrix that supports revascularization, remodeling and regeneration for abdominal wall and hernia repairs.
Recently published data in the American Journal of Surgery from the Brigham and Women's Hospital studied the use of XenMatrix in complex abdominal wall defects and reported a 93 percent success rate with over 16 months follow-up.
Davol, Inc., P.O. Box 8500, 100 Sockanossett Crossroads, Cranston, RI 02920.